Cancer – ADVL1614: Phase 1/2 Study of VX26/3604 in Children, Adolescents or Young Adults with Recurrent or Relapsed Solid Tumors
Condition or Therapy:
Cancer and Blood Disorders
Study Number: ADVL1614
What is the goal of this study?
Researchers want to assess the maximum tolerated dose of pepinemab to be given to children with recurrent or refractory solid tumors.
Who can join the study?
This study may be a good fit for children and young adults who:
- are between 1 and 30 years old, and
- have recurrent or refractory solid tumors or osteosarcoma.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106, or email the study coordinator.